Intended Use:
Wegovy® (semaglutide) is a once-weekly injectable prescription medication used for chronic weight management in adults with:

• A body mass index (BMI) ≥30 kg/m² (obesity), or
• A BMI ≥27 kg/m² (overweight) with at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes, or dyslipidemia).
  It should be used in combination with a reduced-calorie diet and increased physical activity.
  
  

Contraindications:
Do not use Wegovy® if:

• You or any family member has ever had medullary thyroid carcinoma (MTC)
• You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• You are allergic to semaglutide or any of the product’s components
  
  

Warnings & Serious Risks:

• Thyroid tumors, including cancer: In animal studies, semaglutide caused thyroid C-cell tumors. Human relevance is unknown.
• Pancreatitis: Seek immediate care if you experience persistent severe abdominal pain.
• Gallbladder disease: Symptoms may include upper abdominal pain, jaundice, or clay-colored stools.
• Kidney problems: Dehydration from gastrointestinal side effects can worsen kidney function.
• Hypoglycemia: Particularly when used with insulin or sulfonylureas.
• Diabetic retinopathy complications: Monitor for vision changes.
• Suicidal ideation or behavioral changes: Report any new or worsening mood symptoms to your provider.
• Severe gastrointestinal disease: Not recommended in patients with severe GI disorders.

Common Side Effects:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain
• Headache
• Indigestion
• Fatigue
• Injection site reactions
• Gastroesophageal reflux
• Dizziness
• Bloating or gas

These side effects are usually mild and decrease over time with continued use.

Drug Interactions:

• May slow gastric emptying, potentially affecting absorption of oral medications.
• Use with caution alongside:
  • Insulin or insulin secretagogues
  • Oral contraceptives (backup methods may be recommended temporarily)
  • Medications with narrow therapeutic windows (e.g., warfarin)
    
    

Pregnancy & Breastfeeding:

• Wegovy® is not recommended during pregnancy. Discontinue at least 2 months prior to planned conception.
• Unknown if semaglutide is excreted in breast milk. Discuss potential risks and alternatives with your provider if breastfeeding.
  
  

Administration:
Inject subcutaneously once weekly in the abdomen, thigh, or upper arm. Administer on the same day each week, with or without food. Rotate injection sites weekly.

Storage:
Store in the refrigerator (36°F to 46°F / 2°C to 8°C). Do not freeze. Can be stored at room temperature (up to 86°F / 30°C) for up to 28 days.

Emergency Situations:
Seek urgent medical attention if you experience signs of severe allergic reaction, severe GI symptoms, or symptoms of low blood sugar. For life-threatening symptoms, call 911 or visit the nearest emergency room.

Disclaimer:
This information is provided for educational purposes only and is not a substitute for professional medical advice. Consult your healthcare provider before starting or changing any medication. Report adverse effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch